32 completed, 7 terminated, 6 recruiting, 4 unknown. 55 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Completed 32, Terminated 7, Recruiting 6, Unknown 4, Active not recruiting 3, Withdrawn 3 |
| Phase 1 | 7 | Completed 4, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Hemangiosarcoma: new trials by email Literature Review of Hemangiosarcoma trials Research Report on Hemangiosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma Vusolimogene Oderparepvec (VO), Pembrolizumab - Angiosarcoma, Angiosarcoma, Adult | Phase 2 | Recruiting | Varun Monga, MBBS | 18 | 2026-01-09 | 2026-09-01 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically OMX-0407 - Solid Tumor | Phase 1 / Phase 2 | Terminated | iOmx Therapeutics AG | 68 | 2023-03-30 | 2026-07-24 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| Cemiplimab for Secondary Angiosarcomas Cemiplimab - Secondary Angiosarcoma, Locally Advanced Sarcoma | Phase 2 | Completed | Radboud University Medical Center | 18 | 2022-01-01 | 2024-10-31 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study Quality-of-Life Assessment, Sintilimab - Locally Advanced Angiosarcoma, Metastatic Angiosarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-08-23 | 2026-07-21 |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma Ontorpacept (TTI-621), Doxorubicin - Leiomyosarcoma | Phase 2 | Terminated | Pfizer | 76 | 2021-06-22 | 2024-12-11 |
| AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma AGEN2034, AGEN1884 - Angiosarcoma | Phase 2 | Withdrawn | Agenus Inc. | 2021-02-01 | 2022-01-11 | |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Durvalumab, Oleclumab - Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 75 | 2020-11-26 | 2026-06-22 |
| Propranolol in Angiosarcoma Propranolol - Angiosarcoma | Phase 2 | Completed | The Netherlands Cancer Institute | 14 | 2019-12-27 | 2023-11-22 |
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma T-VEC - Angiosarcoma of Skin | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 5 | 2019-08-20 | 2022-11-01 |
| Paclitaxel-Avelumab for Angiosarcoma Avelumab, Paclitaxel - Angiosarcoma Metastatic | Phase 2 | Unknown | Sung Yong Oh | 32 | 2018-06-01 | 2018-07-11 |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Eribulin - Angiosarcoma, Epithelioid Hemangioendothelioma | Phase 2 | Completed | Massachusetts General Hospital | 13 | 2018-01-18 | 2026-08-28 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
Showing 20 of 55. Sign in to see all of them.
Sarcoma (39) · Leiomyosarcoma (28) · Liposarcoma (26) · Sarcoma, Synovial (23) · Fibrosarcoma (22) · Histiocytoma, Malignant Fibrous (22) · Neurofibrosarcoma (21) · Rhabdomyosarcoma (16) · Hemangiopericytoma, Malignant (12) · Sarcoma, Alveolar Soft Part (12) · Malignant mesenchymal tumor (11) · Osteosarcoma (11) · Chondrosarcoma, Extraskeletal Myxoid (8) · Dermatofibrosarcoma (8)
Neoplasms by Histologic Type (55) · Neoplasms, Connective and Soft Tissue (55) · Neoplasms, Vascular Tissue (55) · Neoplasms (54) · Neoplasms, Connective Tissue (33) · Neoplasms, Fibrous Tissue (32) · Neoplasms, Muscle Tissue (29) · Neoplasms, Adipose Tissue (25) · Neoplasms, Nerve Tissue (24) · Histiocytoma (22) · Nervous System Diseases (21) · Nervous System Neoplasms (21) · Neurofibroma (21) · Neuromuscular Diseases (21) · Peripheral Nervous System Diseases (21)
Doxorubicin (9) · Paclitaxel (6) · pazopanib (5) · Bevacizumab (4) · Gemcitabine (4) · Ifosfamide (4) · Docetaxel (3) · Imatinib Mesylate (3) · Nivolumab (3) · Propranolol (3) · Sorafenib (3) · durvalumab (3) · pembrolizumab (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Carboplatin (2)
National Cancer Institute (NCI) (8) · European Organisation for Research and Treatment of Cancer - EORTC (7) · M.D. Anderson Cancer Center (3) · Brown University (2) · Centre Oscar Lambret (2) · Memorial Sloan Kettering Cancer Center (2) · Northwestern University (2) · Agenus Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Daiichi Sankyo (1) · Fox Chase Cancer Center (1) · Fudan University (1) · Grupo Espanol de Investigacion en Sarcomas (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · HRYZ Biotech Co. (1)
United States (30) · France (9) · Belgium (6) · Netherlands (6) · United Kingdom (5) · Denmark (4) · Germany (4) · Spain (3) · Austria (2) · Canada (2) · China (2) · Slovakia (2) · Brazil (1) · Guam (1) · Hungary (1)
Alba Rubio (1) · Annabel B.M. Foot (1) · Antonio Casado (1) · Axel Le Cesne, MD (1) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Camila MV Moniz, Doctor (1) · Charles Theuer, MD (1) · Christophe Bergeron (1) · Christopher W Ryan (1) · Claudia Valverde (1)
PMID 19451433, PMID 31401903, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 18809609, PMID 19088049, PMID 19451429, PMID 20338746, PMID 20471824, PMID 21796368, PMID 22198468, PMID 22285963, PMID 22623692, PMID 22649152, PMID 24005614, PMID 24215845, PMID 24218035, PMID 27406346, PMID 27406347, PMID 28851423, PMID 30305054, PMID 31969335, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 33203665, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34529000, PMID 34716198, PMID 34741021, PMID 35623341, PMID 35934010, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107
P30CA008748 (3), 2009 (2), N01CM62206 (2), 2015 (1), N01CM62201 (1), P30CA006927 (1), P30CA012197 (1), P30CA016672 (1), P30CA060553 (1), U01CA069856 (1), U10CA031946 (1), U10CA032102 (1), U10CA081851 (1), U10CA098543 (1), U10CA180821 (1)